AVEO Oncology
AVEO
$15.00
Share price
0.00%
Change (1 day)
170.76%
Change (1 year)
Categories
P/S ratio for AVEO Oncology (AVEO)
P/S ratio as of April 2024 (TTM): 5.53
According to AVEO Oncology 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.52854. At the end of 2022 the company had a P/S ratio of 3.02.
P/S ratio history for AVEO Oncology from 2010 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 3.02 | -20.76% |
| 2021 | 3.81 | -86.2% |
| 2020 | 27.6 | 692.08% |
| 2019 | 3.49 | -90.68% |
| 2018 | 37.4 | -14.1% |
| 2017 | 43.6 | 167.41% |
| 2016 | 16.3 | 322.7% |
| 2015 | 3.85 | 58.97% |
| 2014 | 2.42 | -96.69% |
| 2013 | 73.3 | 301.26% |
| 2012 | 18.3 | 305.41% |
| 2011 | 4.51 | -61.31% |
| 2010 | 11.6 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 20.4 | 269.18% | 🇺🇸 USA |
 Amgen AMGN | 5.14 | -7.08% | 🇺🇸 USA |
 Biogen BIIB | 3.09 | -44.06% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 7.39 | 33.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.02 | -63.44% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | N/A | N/A | 🇺🇸 USA |